BioSpace News Archive

Nurix Therapeutics, Inc. announced that the company will host a webcast and conference call at 9:00 a.m., ET, on Sunday, June 16, 2024, to discuss data from the ongoing Phase 1 clinical trial of NX-5948 that will be presented in an oral session at the European Hematology Association Congress in Madrid, Spain.

Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced the first patient has been dosed in the Company’s camonsertib monotherapy non-small cell lung cancer (NSCLC) expansion of the TRESR clinical trial.

ImmunoPrecise Antibodies Ltd., a leader in AI-driven biotherapeutic research and technology, announces the commercial release of LENSai API, hereafter referred to as the ‘software’, by its subsidiary, BioStrand.

Bodybuilders and cellular mechanisms agree generating protein is a heavy lift. To complete the task, cells rely on complexes called spliceosomes.

Tharimmune, Inc. reports positive results from its Phase 1 clinical trial with TH104, a proprietary transmucosal buccal film embedded with the approved, active compound nalmefene that easily adheres inside of the mouth on the cheek and biodegrades within minutes.

Crinetics Pharmaceuticals, Inc. announced that on June 10, 2024, the Compensation Committee of Crinetics’ Board of Directors granted non-qualified stock option awards to purchase an aggregate of 158,000 shares of its common stock to nine new non-executive employees under the Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan.

Mirum Pharmaceuticals, Inc. announced that on June 10, 2024, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 56,600 shares of common stock and 28,300 restricted stock units to 14 new employees under Mirum’s 2020 Inducement Plan.

Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that Sergio Traversa, Chief Executive Officer, will participate in a fireside chat at the 2024 Goldman Sachs Global Healthcare Conference in Miami, Florida on Wednesday, June 12, 2024, at 11:20am ET.

Monopar Therapeutics Inc., a clinical-stage radiopharmaceutical company focused on developing innovative treatments for cancer patients, is presenting data from the preclinical development of its novel first-in-class lead radiopharma program MNPR-101-Zr at the 2024 Society of Nuclear Medicine and Molecular Imaging Annual Meeting in Toronto, Canada.

MoonLake Immunotherapeutics announced the successful outcome of its end-of-Phase 2 interactions with the U.S. Food and Drug Administration, as well as positive feedback from its interactions with the E.U.